Advantage Alpha Capital Partners LP Protagonist Therapeutics, Inc Transaction History
Advantage Alpha Capital Partners LP
- $361 Million
- Q1 2025
A detailed history of Advantage Alpha Capital Partners LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 8,634 shares of PTGX stock, worth $474,956. This represents 0.12% of its overall portfolio holdings.
Number of Shares
8,634
Previous 5,742
50.37%
Holding current value
$474,956
Previous $221,000
88.69%
% of portfolio
0.12%
Previous 0.06%
Shares
3 transactions
Others Institutions Holding PTGX
# of Institutions
303Shares Held
61.3MCall Options Held
1.01MPut Options Held
555K-
Farallon Capital Management LLC San Francisco, CA6.11MShares$336 Million1.7% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$317 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.72MShares$315 Million4.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.28MShares$235 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$165 Million5.07% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.7B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...